Telomir Pharmaceuticals (NASDAQ:TELO) Trading 1.5% Higher – Should You Buy?

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shares traded up 1.5% during trading on Monday . The company traded as high as $1.36 and last traded at $1.34. 54,096 shares were traded during mid-day trading, a decline of 34% from the average session volume of 81,803 shares. The stock had previously closed at $1.32.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TELO. Rodman & Renshaw initiated coverage on shares of Telomir Pharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Telomir Pharmaceuticals Trading Down 5.9%

The firm’s 50-day moving average price is $1.26 and its 200-day moving average price is $1.36.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. On average, sell-side analysts expect that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Several institutional investors have recently modified their holdings of TELO. Geode Capital Management LLC lifted its position in Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock worth $297,000 after buying an additional 27,519 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at $95,000. Raymond James Financial Inc. lifted its holdings in shares of Telomir Pharmaceuticals by 4,101.9% in the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after acquiring an additional 73,547 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth about $62,000. Finally, XTX Topco Ltd purchased a new position in shares of Telomir Pharmaceuticals during the 4th quarter worth about $53,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.